290 related articles for article (PubMed ID: 23410127)
1. Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.
Brand LJ; Dehm SM
Curr Drug Targets; 2013 Apr; 14(4):441-9. PubMed ID: 23410127
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
3. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
[TBL] [Abstract][Full Text] [Related]
7. BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.
Lee II; Kuznik NC; Rottenberg JT; Brown M; Cato ACB
J Mol Endocrinol; 2019 May; 62(4):R289-R299. PubMed ID: 30913537
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan SC; Li Y; Dehm SM
J Biol Chem; 2012 Jun; 287(23):19736-49. PubMed ID: 22532567
[TBL] [Abstract][Full Text] [Related]
9. Functional implications and therapeutic targeting of androgen response elements in prostate cancer.
Senapati D; Sharma V; Rath SK; Rai U; Panigrahi N
Biochimie; 2023 Nov; 214(Pt B):188-198. PubMed ID: 37460038
[TBL] [Abstract][Full Text] [Related]
10. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor variants: RNA-based mechanisms and therapeutic targets.
Tietz KT; Dehm SM
Hum Mol Genet; 2020 Sep; 29(R1):R19-R26. PubMed ID: 32412639
[TBL] [Abstract][Full Text] [Related]
13. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
[TBL] [Abstract][Full Text] [Related]
16. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.
Nyquist MD; Li Y; Hwang TH; Manlove LS; Vessella RL; Silverstein KA; Voytas DF; Dehm SM
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17492-7. PubMed ID: 24101480
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
[TBL] [Abstract][Full Text] [Related]
18. Are androgen receptor variants a substitute for the full-length receptor?
Lu J; Van der Steen T; Tindall DJ
Nat Rev Urol; 2015 Mar; 12(3):137-44. PubMed ID: 25666893
[TBL] [Abstract][Full Text] [Related]
19. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.
Nyquist MD; Dehm SM
Horm Cancer; 2013 Apr; 4(2):61-9. PubMed ID: 23307762
[TBL] [Abstract][Full Text] [Related]
20. Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
Wang T; Song W; Chen Y; Chen R; Liu Z; Wu L; Li M; Yang J; Wang L; Liu J; Ye Z; Wang C; Chen K
Clin Cancer Res; 2016 Mar; 22(6):1531-44. PubMed ID: 26527749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
